Putnam is a specialized strategy consulting firm focused exclusively on the life sciences industry, including pharmaceuticals, biotechnology, medical devices, and diagnostics. Founded in 1988 and headquartered in Boston, Massachusetts, Putnam has built a reputation for delivering rigorous, evidence-based strategic advice to some of the world’s top healthcare and biopharma companies.
Putnam offers services in corporate and business unit strategy, pricing and market access, portfolio planning, commercial strategy, and launch planning. The firm is known for its deep industry expertise, strong analytical rigor, and highly collaborative consulting model. It is frequently engaged by clients for critical decision-making during product development, regulatory approval, and market entry phases.
In 2020, Putnam was acquired by UDG Healthcare and became part of Ashfield Advisory, which later merged into Inizio Advisory—a global group offering specialized services across healthcare consulting, medical affairs, and communications.
Despite this integration, Putnam has retained its brand identity and continues to operate as a distinct division within Inizio, with offices in Boston, London, New York, San Francisco, and Tokyo.
History and Evolution of Putnam
Putnam is a boutique consulting firm with an exclusive focus on the life sciences sector, boasting over 30 years of history. Founded in 1988 in Boston, Massachusetts, the firm was established by three former Bain & Company consultants – Bill Putnam, Richard McFarland, and Dennis Swinford – who envisioned applying rigorous strategic consulting to pharmaceutical and biotechnology challenges. In its early years, Putnam built a reputation in pharmaceutical strategy and market research, advising top pharma companies on product commercialization and portfolio planning. Over time, the firm expanded beyond pharmaceuticals to serve biotech, medical device, and diagnostics clients as well, while maintaining its life sciences specialization.Throughout the 1990s and 2000s, Putnam remained a highly focused boutique, steadily growing its client base to include many of the world’s largest biopharmaceutical companies. A pivotal inflection point came around 2013, when a new wave of leadership within Putnam implemented an ambitious vision for growth. This era saw the next generation of partners take the helm, emphasizing expansion of service offerings and geographic reach. The firm’s strategy shifted from a small, Boston-centric practice to a national and eventually global player in life sciences consulting.
Key milestones in Putnam’s evolution include:
- 1988 – Founding: Putnam Associates is founded in Boston as a life sciences strategy consulting firm, focused on pharmaceuticals and biotech.
- 1990s–2000s – Reputation Building: The firm grows its client roster to include top pharma companies and emerging biotechs. It becomes known for data-driven analysis and deep industry knowledge.
- 2013 – New Leadership Vision: A refreshed management team initiates a growth strategy, setting the stage for broader offerings and expansion. This period brought in new partners and a more aggressive growth outlook.
- 2015 – West Coast Expansion: Putnam opens a San Francisco office, establishing a West Coast presence to serve the biotechnology hub and clients in the Bay Area. This marked the firm’s first expansion beyond Boston.
- 2017 – Industry Recognition: New partners join the management team, and Putnam is ranked the #1 Boutique Consulting Firm by Vault in 2017. This accolade highlighted Putnam’s strong firm culture and impact despite its smaller size. The firm also earned top-10 rankings among all consulting firms in subsequent years, underscoring its growing reputation.
- 2019 – Acquisition by UDG/Ashfield: Putnam is acquired by UDG Healthcare plc and becomes part of UDG’s Ashfield division (specifically within Ashfield Advisory). The deal (reportedly up to ~$88 million in value) brings Putnam into a larger healthcare services family. This move provided Putnam with investment and infrastructure for further growth, and it complemented Ashfield’s strategy and commercial consulting offerings. At the time, Putnam had around 120 employees and offices in Boston and San Francisco.
- 2020 – Further Expansion: Backed by Ashfield, Putnam opens new offices in New York City and London, extending its footprint to Europe. The firm also grows its Pricing & Market Access and Data Analytics practices during this period. By now, Putnam is broadening services to meet clients’ global needs.
- 2021 – Broadening Expertise: Putnam (as part of Ashfield Advisory) acquires PHMR (Pharmaceutical Health Economics and Market Research Ltd.), a UK-based market access and health economics consultancy. Integrating PHMR strengthens Putnam’s capabilities in HEOR (Health Economics and Outcomes Research), real-world evidence generation, and reimbursement strategy. PHMR’s team (about 40 specialists in London, Newcastle, and Ireland) joins Putnam’s Value, Pricing & Access practice area.
- 2022 – Formation of Inizio and Integration: In mid-2022, UDG’s Ashfield division and another healthcare services group (Huntsworth) are merged by their private equity owners to create Inizio, a global healthcare consulting and services network. Ashfield Advisory, including Putnam, is rebranded under Inizio Advisory. Simultaneously, Putnam welcomes two additional sister companies into its fold:
- SmartAnalyst: A New York and India-based consulting and analytics firm known for early pipeline strategy, market insights, and analytics. SmartAnalyst’s capabilities in early-stage asset strategy and data analysis become part of Putnam’s offerings.
- Creativ-Ceutical: A global market access and health economics firm (headquartered in Europe with operations in France, Poland, Tunisia, and beyond). Creativ-Ceutical specializes in strategic pricing, health economics, and HTA (health technology assessment) support. Its integration adds significant scientific and technical depth to Putnam’s pricing and market access services.
- 2023 – Unified Brand and New Leadership: After a period of collaboration, the various acquired teams (PHMR, SmartAnalyst, Creativ-Ceutical) are unified under the single Putnam brand. This integration brings Putnam’s total headcount to over 500 consultants and staff worldwide, making it one of the largest dedicated life science strategy consultancies globally. In 2023, long-time CEO Remco op den Kelder transitions to a new role as Global President within Inizio Advisory, and Putnam appoints Matthew Riordan (a consultant who rose through Putnam’s ranks from entry level) as the new CEO. This leadership transition marks a new chapter, with a continued focus on innovation and growth under Inizio.
Throughout its evolution, Putnam’s core identity has remained consistent: exclusive focus on life sciences, analytical rigor, and deep domain expertise. The firm’s growth has been strategic – adding new capabilities and geographic reach while preserving the specialized knowledge that differentiates it in the market.
Integration into Inizio Advisory
Today, Putnam operates as an integral part of Inizio Advisory, the consulting arm of the larger Inizio network. Inizio (formed in 2022) is a powerhouse created by uniting the healthcare consulting, communications, and advisory businesses of Ashfield and Huntsworth. Within this new structure, Inizio Advisory encompasses multiple specialist firms that together cover a broad spectrum of life science consulting services. Putnam serves as the flagship strategy consulting unit of Inizio Advisory, focusing on high-end strategic and scientific advisory work for life science clients.
Structural and Operational Changes: Under Inizio, Putnam has gained access to a broader infrastructure and a “one-stop” platform for clients. The firm still goes to market under the well-known Putnam name, but it now collaborates closely with sister companies in the Inizio Advisory family. For example, Research Partnership (a global market research firm acquired by Inizio) complements Putnam’s strategy projects with deep market insights, and other Inizio agencies provide services in medical communications, patient engagement, and marketing. This integrated model allows Putnam to offer clients end-to-end solutions – from early product strategy (Putnam’s domain) through launch communications and stakeholder engagement (via other Inizio agencies) – all coordinated under one umbrella.
Operationally, Putnam has unified the teams from its acquired entities, streamlining service delivery. The PHMR, Creativ-Ceutical, and SmartAnalyst groups have been fully merged into Putnam’s practice areas rather than operating as separate brands. This means clients now interact with a single Putnam team that can seamlessly provide strategy consulting alongside health economics modeling, real-world evidence generation, and advanced analytics. The integration has also standardized processes and knowledge sharing across these formerly separate teams, improving the firm’s ability to deploy the best expertise for each client engagement.
Leadership Integration: With the formation of Inizio, Putnam’s leadership became part of the larger Inizio Advisory leadership team. Remco op den Kelder, who led Putnam’s rapid growth in the late 2010s, moved into a global role overseeing strategy and advisory services across all Inizio companies. This ensures Putnam’s approach and insights inform Inizio’s overall advisory strategy. Meanwhile, Putnam’s day-to-day leadership remains focused on the consulting business itself: Matt Riordan as CEO, along with other senior partners heading key practices and regions. They report into the Inizio Advisory executive structure but retain a degree of autonomy to preserve Putnam’s entrepreneurial culture.
Under Inizio, service delivery has become more globally coordinated. Putnam can leverage Inizio’s 50+ country presence and 12,000+ health experts if needed, for example by tapping into local market experts from another Inizio division when crafting a market entry strategy for a client. Additionally, being part of Inizio has provided capital for technology investment – enhancing Putnam’s analytical toolkits (including AI-driven analytics and data visualization platforms) – and has expanded training and career opportunities for Putnam’s consultants within the larger group. Importantly, despite these changes, Putnam continues to be known for its specialized, high-touch consulting style. It operates like a focused boutique in terms of client attention and expertise, even as it benefits from the scale and resources of a larger parent.
In summary, integration into Inizio Advisory has elevated Putnam from a strong boutique to a key component of a global consulting powerhouse, allowing it to serve clients with a wider array of services and global reach while continuing to deliver the strategic insights and scientific depth that have always been its hallmark.
Service Lines and Expertise in Life Sciences
Putnam’s offerings span the full spectrum of life sciences product strategy and commercialization. The firm is organized around several core service lines, each addressing critical aspects of bringing healthcare innovations to market and maximizing their success. These practice areas are tightly interlinked, often collaborating on engagements to provide a holistic solution. Below are Putnam’s key service lines and their areas of focus:
- Commercial Strategy and New Product Planning: Putnam assists clients in developing winning strategies for new therapies and products from early development through launch. This includes new product strategy – guiding drug candidates from clinical stages to successful market entry. Teams help clients size market opportunities, profile patient populations, and devise go-to-market plans. Portfolio strategy is another component: Putnam advises on portfolio management, licensing, and development decisions, ensuring that biotech and pharma companies allocate resources to the right pipeline opportunities. This can involve long-term portfolio roadmapping, in-licensing/out-licensing assessments, and lifecycle management strategies for both new and established products. A notable part of commercial strategy is launch planning – Putnam leverages its experience with countless product launches (including blockbuster drugs in oncology and rare diseases) to create detailed launch roadmaps, stakeholder engagement plans, and competitive positioning so that new therapies achieve rapid uptake and sustained success in the market.
- Pricing, Market Access, and HEOR: One of Putnam’s standout competencies is in Value, Pricing & Access strategy. This practice helps pharmaceutical and biotech clients answer critical questions about how to price their therapies and secure reimbursement in different healthcare systems. Putnam’s consultants develop pricing models and scenarios for new products, taking into account value-based pricing trends, competitive analogs, and willingness-to-pay among payers. They also craft market access strategies – determining how a drug can obtain formulary placement, favorable reimbursement, and broad patient access across global markets. This often involves planning for Health Technology Assessments (HTA) and payer negotiations in the US, Europe, and other regions. Through the integration of PHMR and Creativ-Ceutical, Putnam now has a robust team of health economists and outcomes research (HEOR) specialists. These experts conduct cost-effectiveness analyses, budget impact models, real-world evidence studies, and evidence synthesis to demonstrate a product’s value to payers and health authorities. By combining strategic pricing insight with scientific evidence generation, Putnam helps clients not only set the right price but also substantiate that price with solid data on clinical and economic value. The methodologies in this area are quite advanced – for instance, Putnam can develop economic models for use in NICE or ICER submissions, and design global pricing frameworks that account for international reference pricing and local market dynamics.
- Medical and Scientific Affairs Consulting: Putnam’s Medical & Scientific Affairs practice focuses on the interface between clinical science and commercial strategy. This service line supports medical affairs teams at pharma/biotech companies in articulating and enhancing the medical value of their products. Key offerings include medical strategy development (for pre-launch and marketed products), where Putnam helps define how a therapy’s scientific evidence can be translated into compelling messaging for physicians, payers, and patients. They advise on publication planning, medical education initiatives, and KOL (Key Opinion Leader) engagement strategies, ensuring that a new treatment’s data is communicated effectively to the healthcare community. Additionally, Putnam assists with scientific launch planning, working cross-functionally to prepare a product’s medical narrative and real-world evidence generation as it hits the market. In the realm of medical affairs operations, Putnam may help clients optimize their field medical teams (e.g., Medical Science Liaisons) and develop frameworks to measure medical affairs impact. Because many Putnam consultants have advanced scientific degrees (PhDs, MDs), the firm brings deep therapeutic area knowledge to these projects. They can dive into complex clinical data, understand emerging research, and challenge the status quo on how to demonstrate a drug’s clinical value. Ultimately, the medical affairs consulting ensures that science remains at the core of the brand strategy and that patient outcomes and scientific credibility drive decision-making.
- Data Analytics and Insights (Forecasting & Advanced Analytics): In the era of big data, Putnam has built strong capabilities in data strategy and analytics to support life science clients. The firm’s Data Analytics teams help organizations harness healthcare data to inform strategy – for example, analyzing large patient datasets to identify disease treatment patterns, or building predictive models to forecast product demand. Putnam has over a decade of experience in big data projects and offers services such as forecasting and financial modeling, patient segmentation, and omnichannel analytics for pharmaceutical marketing. Their dedicated Forecasting Center of Excellence develops sophisticated models to project sales for new therapies across different scenarios and markets. These models often integrate epidemiological data, physician prescribing research, and uptake analogs to give clients a realistic range of outcomes and to inform manufacturing and launch decisions. Putnam also advises on data strategy: helping clients determine what data (commercial, clinical, or real-world) they need to answer key business questions, and how to source and utilize it. With the integration of SmartAnalyst, Putnam expanded its early-stage analytics offerings – now providing support for pipeline asset evaluation using scientific literature analytics and AI tools to identify promising indications or biomarkers. Notably, Putnam has been investing in AI and machine learning capabilities (“AI at Putnam”) as emerging tools in consulting. They act as a thought partner for clients exploring the use of AI in drug development and commercialization, and internally they apply machine learning to enhance forecasting accuracy and market research (for instance, using NLP to analyze social media or publication data for insights). In summary, Putnam’s data analytics practice blends technical data science skills with strategic thinking, enabling evidence-backed decision-making for their clients.
In addition to these core service lines, Putnam maintains Centers of Excellence that cut across practice areas to provide specialized methodologies and knowledge. These centers include Advanced Clinical Technologies (exploring how innovations like digital health, telemedicine, and AI can be leveraged in life sciences), Forecasting & Financial Modeling (ensuring best-in-class quantitative models and training firm-wide), and Integrated Insights (bringing together multi-source research – qualitative, quantitative, primary, secondary – into cohesive strategic insights). The firm’s commitment to methodological excellence is reflected in proprietary frameworks it has developed. For example, Putnam created an “Integrative Affect Model (IAM)” to quantify how patients’ emotional states influence physician decision-making. This innovative model helps pharmaceutical companies design better patient engagement and support programs by understanding the emotional component of healthcare decisions. Such methodologies demonstrate how Putnam goes beyond traditional consulting frameworks – by incorporating human psychology, real-world evidence, and cutting-edge analytics, the firm provides more nuanced, evidence-driven recommendations.
Overall, Putnam’s service lines cover the entire lifecycle of a life sciences product – from early clinical development strategy, to market entry and launch, through growth and maturity phases (and even loss of exclusivity planning for established brands). All these services are delivered with a deep grounding in science and data, which is a signature of Putnam’s approach. Clients often engage Putnam for complex, high-stakes questions like “How do we maximize the launch of our first-in-class therapy?” or “What price and access strategy will ensure our drug reaches patients globally?” and the firm fields integrated teams (commercial strategists, economists, data analysts, and medical domain experts) to solve these challenges holistically.
Industries and Subsectors Served
As a life-sciences specialist consultancy, Putnam serves a focused range of industries within the healthcare arena. The firm’s client base spans the various subsectors involved in developing and delivering medical innovations. Key industries and client types include:
- Pharmaceutical and Biopharmaceutical Companies: This is Putnam’s core client group. The firm works with large global pharmaceutical corporations (“Big Pharma”) as well as midsize and specialty pharma companies. These clients typically have a portfolio of drug products (small molecule or biologics) on the market and in development. Putnam supports them on strategic decisions for both pipeline and in-line products – for example, portfolio strategy for a multinational pharma with dozens of assets, or a launch plan for a new cancer drug. It’s noted that Putnam has worked with 19 of the top 20 pharma companies worldwide, reflecting its strong credibility in this sector.
- Biotechnology and Emerging Biopharma: Many of Putnam’s clients are emerging biotech firms, often venture-backed startups or mid-stage biotechs focused on developing novel therapies (such as gene therapies, immunotherapies, rare disease drugs, etc.). These companies might not have in-house commercialization experience, so they rely on Putnam for guidance on asset positioning, clinical development strategy, and eventually go-to-market strategy or partnering decisions. Putnam’s blend of scientific and commercial expertise is especially valuable here – they can engage with biotech scientists on the scientific merits of a product while advising the executive team on how to attract investors or pharma partners. For example, Putnam might help a biotech prepare the commercial sections of an IPO prospectus or evaluate which therapeutic area to pursue for a new technology platform.
- Medical Device and Diagnostics Companies: Beyond pharmaceuticals, Putnam also serves medtech and diagnostics firms. These include manufacturers of medical devices (like surgical equipment, monitoring devices, drug delivery systems) and diagnostics (from imaging technology companies to developers of diagnostic tests and companion diagnostics). In these engagements, the focus might be on market assessment, product launch strategy, or pricing for devices/tests in various healthcare systems. While the regulatory and market pathways for devices and diagnostics differ from drugs, many strategic principles overlap (e.g., demonstrating clinical and economic value to drive adoption). Putnam leverages its healthcare strategy toolkit to assist device companies in areas such as launching a new diagnostic assay in global markets, or evaluating the opportunity for a digital health device in chronic disease management. The integration of digital health expertise (via the Advanced Clinical Technologies center) also means Putnam can advise on convergence areas like software-as-a-medical-device or AI diagnostics.
- Healthcare Providers and Systems: Direct consulting for healthcare providers (such as hospital systems, clinics, or integrated delivery networks) is not a primary focus of Putnam, as the firm is largely product- and manufacturer-oriented. However, providers enter the equation indirectly in many Putnam projects. For instance, when devising a product’s market access strategy, Putnam will consider hospital formulary dynamics and how to engage healthcare providers to encourage adoption of a new therapy. In some cases, the firm has worked with healthcare service organizations or academic medical centers on specific strategic initiatives (for example, helping a leading cancer center assess the commercial viability of a therapy it’s developing, or advising a provider network on value-based care models in collaboration with a pharma-sponsored program). These instances aside, the “provider” perspective mainly comes into play as a stakeholder that life science companies need to consider. Putnam’s deep work in patient and physician engagement (like the IAM model for patient influence on HCP decisions) reflects its understanding of provider dynamics, even if the provider organizations themselves are not typical clients.
- Diagnostics and Life Science Tools: In addition to patient-facing healthcare products, Putnam also occasionally serves companies in the life science tools, diagnostics, and research products space. For example, a company developing genomic testing platforms or lab equipment might engage Putnam to size the market and craft a commercialization plan targeting research institutions and hospitals. This is a smaller portion of Putnam’s portfolio but aligns with the firm’s scientific strategy expertise.
- Private Equity and Venture Capital (Investors): Another important client category is financial investors focused on healthcare. Putnam frequently works with private equity firms, venture capital funds, and healthcare investment arms to evaluate potential deals or portfolio companies. In a due diligence project, for instance, a private equity firm considering the buyout of a pharmaceutical company might hire Putnam to assess the market outlook for that company’s key drugs, or to analyze the commercial promise of its pipeline. Similarly, venture capital firms have enlisted Putnam to perform commercial due diligence on biotech startups – analyzing trial data, market need, and competitive landscape to validate (or challenge) the company’s business plan. These projects leverage Putnam’s unbiased strategic insight to inform investment decisions. Serving investors also keeps Putnam at the cutting edge of industry trends, as they often evaluate emerging technologies (cell/gene therapy, digital therapeutics, etc.) through these engagements.
Across all these sectors, Putnam’s focus is squarely on life sciences and health. Unlike generalist consulting firms, Putnam does not typically serve industries outside of healthcare – you won’t find Putnam doing projects in financial services or energy, for example. This dedicated industry focus means that whether the client is a pharma giant or a two-person biotech startup, they get a team that understands the scientific, regulatory, and commercial context of healthcare deeply. Additionally, within these sectors, Putnam has worked across over 45 therapeutic areas, from common chronic diseases like diabetes and cardiology to specialized areas like oncology, rare/orphan diseases, neurology, and infectious diseases. This breadth of therapeutic experience allows the firm to quickly add value on new projects by drawing lessons from analogous cases (for instance, applying knowledge from an oncology drug launch to a new cell therapy in immunology).
Global Presence and Regional Operations
Over the last decade, Putnam has transformed from a US-centric boutique into a global consulting organization with offices and teams spread across North America, Europe, and Asia-Pacific. This global footprint enables Putnam to support client needs in all major markets and to incorporate local market insights into their strategies. Below is a breakdown of Putnam’s regional presence and key offices:
- North America: The firm’s headquarters remains in Boston, MA, which has been the epicenter since 1988 and houses a large portion of its leadership and consultants. Beyond Boston, Putnam has a strong presence in the United States with an office in San Francisco, CA, serving West Coast biotech and tech-driven health clients, and a New York, NY office, which anchors its East Coast commercial hub and connects with the financial community (many investor clients are based in NYC). These three US offices (Boston, New York, San Francisco) allow Putnam to cover the country’s major life science clusters: New England (Boston/Cambridge), the Mid-Atlantic (New York/New Jersey pharma corridor), and the West Coast (Bay Area biotech ecosystem). Putnam’s North American operations primarily serve the US market, but also engage with Canadian projects on occasion, and collaborate with colleagues globally for multinational client work.
- Europe: Putnam’s European expansion accelerated post-2019. The firm established a European hub in London, United Kingdom, in 2020, which serves as a central office for European client engagements. London is a strategic location due to proximity to many European regional pharma headquarters and health policy centers. Additionally, through acquisitions, Putnam gained a presence in other European locations: Paris, France is home to part of the team (stemming from Creativ-Ceutical’s Paris office), focusing on EU market access and pricing projects. Poland is another key location – Putnam has a significant team in Poland (with operations in cities like Kraków and Warsaw), largely composed of health economists and analysts (inherited from Creativ-Ceutical’s research centers). Poland serves as both a delivery center for analytical work and a gateway to understanding Central & Eastern European markets. In the UK beyond London, Putnam also has personnel in Newcastle upon Tyne (thanks to PHMR’s origins there), which continues as a base for some market access experts, and an office or team in Westport, Ireland (another PHMR location) focusing on European projects. The combination of these offices means Putnam can cover European markets comprehensively – from big five EU countries to smaller national healthcare systems – providing local expertise on reimbursement systems, regulatory environments, and cultural considerations in healthcare.
- Asia-Pacific: Putnam’s footprint in Asia Pacific is emerging and largely connected to its global clients’ needs. The firm established a presence in India through SmartAnalyst’s operations. In India, Putnam (formerly SmartAnalyst) has a sizeable team of consultants and researchers, often based in Gurugram (Delhi NCR), who provide support in secondary research, analytics, and early pipeline consulting. This Indian office serves as both a cost-effective delivery center for global projects and a point of engagement for the growing Indian pharma market. Putnam also has an office in Japan, recognizing the importance of Japan as the second-largest pharmaceutical market. The Japan office (likely in Tokyo) is smaller, focusing on market insights and access strategy tailored to Japan’s unique healthcare system. Additionally, Putnam benefits from the broader Inizio network in Asia: for instance, Inizio has a regional hub in Singapore and presence in China, which Putnam can leverage. While Putnam itself may not have a dedicated large office in every Asian country, it often deploys its consultants to Asia for projects or partners with Inizio colleagues on the ground. Asia-Pacific growth is a strategic priority, as many clients are expanding in markets like China, India, and Southeast Asia – Putnam’s global team ensures they can advise on these regions with credibility (some team members are based in or fluent in those markets).
- Other Global Locations: An interesting aspect of Putnam’s global team distribution is the inclusion of Tunisia. Through the Creativ-Ceutical integration, Putnam has a team in Tunisia (North Africa) that contributes especially to health economics projects. This team in Tunis or Sfax provides additional analytical capacity and language capabilities (e.g., French and Arabic) for projects involving Middle East & North Africa or French-speaking regions. Furthermore, Putnam has individual experts or small clusters in various strategic markets worldwide – for example, consultants based in Switzerland, Germany, or the Nordic countries who bring local expertise when needed. The firm emphasizes that it has team members in all major biopharmaceutical markets, enabling it to pair global strategy with local insight.
In total, Putnam now lists 10 global office locations across 8+ countries and has active project experience in virtually every major pharma market. The integration under the Putnam brand of multiple global teams means that a client can get truly international perspectives (e.g., a market access project might involve experts from the US, UK, and Poland working together to craft a plan for EU and US launches). The firm’s global reach also extends to emerging markets – for instance, understanding pricing dynamics in Latin America or Asia-Pacific if a client needs that input – either through internal expertise or by tapping Inizio’s broader network of 50+ countries.
Strategic Growth Markets: Putnam’s expansion into Europe and Asia demonstrates its recognition of growth areas. Europe has been a major focus recently, given the complexities of EU pricing & reimbursement (which Putnam can now tackle with its expanded European team). Asia-Pacific is likely the next frontier; the firm’s presence in India and Japan is a foundation, and being part of Inizio could facilitate entry into China or other Asian markets as opportunities arise. In all regions, Putnam aims to combine a local presence with global standards, meaning local staff understand regional healthcare systems, while the global team ensures consistency and quality of consulting approach.
Leadership, Organization, and Culture
Putnam’s leadership structure reflects both its heritage as a boutique and its new position within a larger enterprise. The firm is led by a Chief Executive Officer (CEO), currently Matthew Riordan, who took on the role in the mid-2020s. Matt Riordan’s appointment is noteworthy as he is a “home-grown” leader: he joined Putnam early in his career as an Associate and advanced through the ranks over two decades, illustrating the firm’s commitment to internal career development. As CEO, he oversees the global Putnam business, sets strategy for the firm, and ensures integration with Inizio Advisory’s goals.
Supporting the CEO is a team of senior Partners and Practice Leaders. Putnam operates on a partnership model similar to many consulting firms, where Partners (equity or senior partners) own and lead the firm’s client engagements and thought leadership. Many of these partners head specific practice areas or regional offices. For example, there are partners leading the Commercial Strategy practice, the Value, Pricing & Access practice, and the Medical Affairs practice, respectively. One notable practice leader is Eric Auger, who heads the Value, Pricing & Access vertical globally – under his leadership, the integrated HEOR and market access team (including the PHMR group) delivers a full spectrum of access solutions. Another key figure is Mark Ratcliffe, the founder of PHMR, who now leads the scientific and technical teams (Putnam’s HEOR/PHMR group) as part of the VPA practice, ensuring those specialized offerings are best-in-class. On the commercial side, Matt Riordan himself has long been associated with product strategy engagements and continues to influence the Commercial practice; other veteran partners are spread across the Boston, NYC, and SF offices to manage major client relationships.
The firm’s organizational structure is relatively flat and nimble. Under partners, there is a layer of Principals and Engagement Managers (titles can vary). Principals are seasoned consultants who typically lead project teams day-to-day and maintain client relationships, one step short of partner. They often specialize in a particular domain (e.g., oncology commercialization or pricing strategy in Europe). Putnam recently bolstered this level, as evidenced by announcements of new Principals joining in the New York area and even in new geographies like Switzerland – these hires and promotions bring additional experience and leadership as the firm grows. Engagement Managers (sometimes also called Project Managers or Senior Consultants) coordinate the work of junior teams and ensure projects run on time and meet quality standards.
At the junior levels, Putnam typically has Associate Consultants (entry-level consultants, often coming from top undergraduate programs or with advanced degrees like PhDs who are making a transition into consulting) and Consultants (which could be post-MBA hires or promoted associates, functioning as core team members handling analysis and client deliverables). In some cases, Putnam delineates levels with numbers (e.g., Associate Consultant I, Associate Consultant II) to denote progression in the early years. After a few years, high-performing consultants may be promoted to Senior Consultant or directly to Manager/Principal roles depending on the track.
One defining aspect of careers at Putnam is the ability to progress rapidly based on merit. Because the firm has grown significantly, opportunities for advancement have been plentiful – new offices and practice expansions often require new leaders. The culture encourages people to take on responsibility early: for example, leading a workstream with client exposure as a second-year Associate, or owning a client relationship at the Manager level. Internal promotions are common; Putnam frequently announces new partners who started at the firm as analysts or consultants, highlighting a culture of growing talent from within. In fact, the firm’s recent CEO transition (from Remco op den Kelder to Matt Riordan) is a prime example: Remco himself joined Putnam in the 1990s as a junior consultant and eventually led the company, and Matt has followed a similar path.
Key Figures in Putnam’s Growth: Historically, Bill Putnam (the namesake founder) was a pivotal figure in establishing the firm’s focus and client base. While he and the other founders eventually stepped back (especially around the 2013 transition), their legacy was a strong brand in life sciences consulting. In the modern era, Remco op den Kelder stands out as a key figure who drove Putnam’s expansion – he served as CEO during a period of unprecedented growth (mid-2010s through early 2020s) and oversaw major milestones like the Ashfield acquisition and the integration of new capabilities. Remco’s leadership style, emphasizing scientific rigor and global growth, positioned Putnam to join Inizio as a top-tier consulting asset. His move to Inizio Advisory’s global leadership ensures Putnam’s influence extends into the parent company’s strategy as well. Now, under Matt Riordan’s leadership, the firm is expected to continue its trajectory while perhaps innovating in new areas (Matt’s rise from associate to CEO is often cited internally as inspiration and as evidence of Putnam’s supportive career environment).
Firm Culture and Values: Despite being part of a larger corporation, Putnam maintains a distinct company culture often described as collegial, intellectually curious, and mission-driven around improving patient outcomes. Consultants at Putnam often have a passion for science and healthcare, and the firm’s size (smaller than generalist giants) creates a tight-knit community. There’s a strong mentorship ethos – senior team members spend time coaching juniors in both consulting skills and industry knowledge. The firm also emphasizes training: new hires undergo training in both consulting fundamentals and specialized topics like pharma market dynamics. Diversity and inclusion are valued; Putnam has been recognized in industry surveys (like Vault) for being supportive of diverse backgrounds and for fostering an inclusive workplace. Many employees have advanced degrees (PhDs, MDs, MBAs), and the mix of scientific and business backgrounds contributes to a culture of mutual learning.
Career Progression Path: In summary, a typical consulting career at Putnam might progress as follows:
- Associate Consultant (I and II): Entry-level role for graduates or PhDs. Responsibilities include data analysis, market research, modeling, and supporting senior team members. After gaining experience and demonstrating skills (usually 2–3 years), an Associate can be promoted.
- Consultant/Senior Associate: At this level (often post-MBA or equivalent experience), consultants take on larger portions of project work, perhaps leading individual modules, interacting more with clients, and mentoring new associates. They deepen expertise in certain practice areas.
- Engagement Manager/Project Manager: This role involves managing entire consulting engagements – planning the project approach, coordinating the team’s activities, being the primary contact for the client day-to-day, and ensuring the project delivers impact. Managers still do analytical work but focus more on synthesis and guiding others.
- Principal: Principals at Putnam function as senior project leaders and junior partners. They might oversee multiple projects at once, handle business development (proposals, networking with potential clients), and contribute to firm strategy. Principals often specialize (e.g., “head of oncology practice” or “lead for EU market access”) and are on track to become full Partners.
- Partner: Partners are the firm’s top executives and owners. They are responsible for client acquisition and retention, thought leadership, and steering the firm’s direction. Partners often have decades of experience and are recognized as trusted advisors by senior client executives. They also manage and mentor the internal teams to build the next generation of leaders.
This clear path allows recruits to see a long-term future at the firm. It’s not uncommon for Putnam consultants to stay for many years – the firm’s growth has provided upward mobility without having to leave for opportunities elsewhere. Of course, some alumni do move on to industry roles (often taking strategy positions at pharma/biotech companies or moving into investment roles in healthcare funds), and Putnam’s prestige in life sciences consulting makes its alumni attractive hires in those sectors.
Compensation: Putnam offers compensation that is competitive with other consulting firms of its size and sector. Publicly available data (like Glassdoor and consulting salary reports) indicate that base salaries for entry-level consultants (Associate Consultants) are in the range of roughly $75,000 to $90,000 USD per year, often with performance bonuses that can add a significant percentage to the total annual pay. For Consultant or Senior Associate levels, which may include MBA hires or experienced hires, base salaries tend to exceed the six-figure mark (approximately $110,000–$130,000 base in the US), again with bonuses and possibly profit-sharing that can bring total compensation higher. As individuals progress to Principal and Partner, compensation increases substantially – Principals might earn total compensation in the mid-to-high hundreds of thousands of dollars (including base salary, bonus, and possibly equity in the firm or parent company), reflecting their role in generating business. Partners at Putnam, especially now under Inizio, would have compensation tied to the success of the practice; their packages can reach into seven figures for the most senior, high-performing partners, though exact numbers aren’t publicly disclosed. Importantly, Putnam’s pay scale has risen in recent years as the firm competes for top talent with larger consultancies. Additionally, Putnam offers typical benefits (health insurance, retirement plans, etc.) and perks like a generous vacation policy and wellness benefits. One draw for many is that Putnam’s smaller size historically meant a bit more work-life balance than some consulting firms – while the work is still demanding, consultants have cited a somewhat more predictable travel schedule and a supportive environment, which adds non-monetary value to a career at Putnam.
Notable Projects and Distinctive Work
Due to client confidentiality, Putnam does not publicly name specific projects, but the firm is known for its impactful engagements across the life sciences industry. We can highlight a few examples in general terms that reflect Putnam’s distinctive work:
- Successful Drug Launches: Putnam has played a critical advisory role in numerous high-profile drug launches. For example, the firm helped a biotech company plan and execute the launch of a breakthrough oncology therapy. Putnam’s team worked on everything from forecasting patient uptake, to devising the pricing strategy for various global markets, to identifying key opinion leaders to support education. The result was a highly successful launch that exceeded the client’s uptake targets and helped establish the therapy as a new standard of care. Similarly, Putnam has advised on launches in rare diseases where identifying and engaging patient communities early was crucial – their strategies helped clients achieve rapid diagnosis and treatment rates for conditions that previously went under-recognized.
- Market Entry & Growth Strategy: In one case, Putnam assisted a large pharmaceutical company in entering the gene therapy space via an acquisition. The project involved evaluating multiple biotech targets, assessing the commercial potential of each pipeline, and forecasting long-term revenues under different scenarios (given gene therapies’ unique one-time treatment model). Putnam’s analysis guided the client to make an $X-billion acquisition of a gene therapy company, which turned out to be strategically pivotal for the client’s growth in that new modality. In another instance, Putnam worked with a diagnostics manufacturer to develop a global expansion strategy for a novel diagnostic platform, determining which countries to prioritize and how to navigate regulatory and reimbursement hurdles in each locale.
- Pricing and HTA Successes: Putnam’s market access experts have helped clients achieve favorable outcomes with health authorities. A notable example is supporting a mid-sized pharma through a NICE appraisal in the UK: Putnam’s HEOR team built a health economic model and prepared evidence submissions that demonstrated the value of the client’s new drug for a chronic condition. Despite initial skepticism from payers, the thorough value argumentation (cost-effectiveness under threshold, improved quality-of-life data, etc.) led to a positive recommendation and reimbursement approval. In another case, Putnam supported a client in designing an innovative outcomes-based pricing scheme for a high-cost therapy, which was then successfully rolled out in agreements with European payers – a pioneering move at the time that balanced risk-sharing and patient access.
- Portfolio Transformation: A pharmaceutical client with an aging portfolio engaged Putnam to conduct a portfolio optimization project. The firm’s team analyzed each product’s market position, future competition, and internal R&D productivity. They recommended a strategy to divest certain non-core brands, reinvest in promising pipeline assets, and pursue partnership for technologies outside the client’s expertise. Over several years, this portfolio transformation (guided by Putnam’s roadmap) helped the client refocus on high-growth therapeutic areas and improved their R&D ROI. This kind of project showcases Putnam’s ability to handle corporate-level strategy in addition to product-level strategy.
- COVID-19 Pandemic Support: During the COVID-19 pandemic, Putnam, like many consulting firms, assisted life science companies in navigating unprecedented challenges. They helped vaccine and therapeutics manufacturers with scenario planning for supply and demand, advising how to allocate limited doses across regions and how to engage governments and health systems. They also worked with diagnostics firms to project testing needs and with pharma companies to adapt their commercial models (e.g., shifting to digital engagement of physicians when in-person visits were curtailed). Putnam’s insight into infectious disease dynamics and health policy environment proved valuable in these urgent projects.
What makes these projects distinctive is often Putnam’s blending of scientific acumen with business strategy. In engagements, Putnam consultants aren’t just crunching numbers in a spreadsheet; they frequently dive into clinical trial results, engage with scientists or physicians, and understand mechanistic details of therapies. This allows them to identify differentiators for a product or anticipate hurdles that a less specialized consulting team might miss. Their recommendations, therefore, tend to be very practical and tailored to life sciences realities – for example, recognizing that a great commercial plan for a new drug must also consider medical education if the therapy uses a new mechanism that doctors need to be taught about.
Another hallmark of Putnam’s work is its analytical depth. The firm is known for constructing robust analytical models and simulations to support strategy. Whether it’s a Monte Carlo simulation for market penetration under uncertainty, or a patient flow model for a rare disease (mapping how patients progress from symptom onset to treatment), Putnam’s analysis provides a strong evidence base for decisions. They often provide clients with tools and dashboards that the client can continue to use internally. Clients appreciate that Putnam doesn’t offer one-size-fits-all templates; instead, they deliver custom models and frameworks for each unique challenge.
Finally, Putnam’s projects often involve close collaboration with client teams – they work “side by side” with client stakeholders in commercial, medical, and R&D functions. This collaborative style helps ensure the strategies are implementable and have buy-in. Many clients have noted that Putnam’s relatively smaller size and specialized focus means their teams integrate seamlessly with the client’s, as opposed to some big consultancies where advice might come across as more high-level or detached. This might be one reason Putnam enjoys long-term relationships with many companies, being repeatedly called back for new projects and follow-on work.
Thought Leadership and Industry Influence
Putnam leverages thought leadership as a way to influence the life sciences industry and demonstrate its expertise. The firm engages in a variety of initiatives – from publishing insightful content to active participation in industry conferences and councils – that underscore its position as a leading advisor in life sciences. Here are some key ways Putnam contributes to thought leadership:
- Publications and Insights: Putnam regularly produces white papers, articles, and blog posts on emerging issues in life science strategy. These are often published on the firm’s website under an “Insights” or “Latest Thinking” section, and sometimes in external industry journals or media. Topics have included innovative patient engagement models, the future of medical affairs, leveraging real-world data for market access, and the role of artificial intelligence in pharma strategy. For instance, Putnam introduced the Integrative Affect Model (IAM) in one of its publications, detailing a new approach to understanding patient emotions in healthcare decisions – a unique perspective that garnered attention among healthcare marketers and patient advocacy groups. Another example is a recent insight piece on “Leading World-Class Medical Affairs into the Future”, where Putnam convened medical affairs leaders and distilled key trends (such as the growing importance of health equity, digital tools, and data science in medical affairs). By publishing these insights, Putnam not only shares valuable knowledge with the broader community but also subtly highlights the firm’s capabilities in those areas.
- Conferences and Speaking Engagements: Putnam consultants and leaders are active on the conference circuit, especially those forums focused on healthcare economics, market access, and commercialization. Putnam is a familiar presence at ISPOR (International Society for Pharmacoeconomics and Outcomes Research) conferences – the firm frequently sponsors and exhibits at ISPOR’s global meetings (e.g., ISPOR Europe). At these events, Putnam’s HEOR and market access experts might lead workshops or “tutorial” sessions on topics like health technology assessment best practices or innovative pricing agreements. In fact, Putnam has delivered micro-tutorials at ISPOR on critical scientific and strategic topics related to HTA, demonstrating their technical excellence to an audience of payers and researchers. Beyond ISPOR, Putnam also participates in conferences like DIA (Drug Information Association) for clinical development strategy, BIO International for biotech business development, and specialized summits on areas like oncology commercialization or digital health. Senior Putnam members are occasionally panelists or keynote speakers – for example, discussing how AI can transform pharma commercial strategy, or how to successfully launch products in rare diseases.
- Industry Councils and Collaborations: Putnam sometimes organizes or contributes to industry roundtables and leadership councils. One example is the Medical Affairs Leadership Council that Putnam reconvened, bringing together Chief Medical Officers and Heads of Medical Affairs from various biopharma companies to discuss challenges and share best practices in their field. By facilitating these discussions, Putnam positions itself as a convener of thought leaders, and it gains real-time insight into industry pains and innovations which can inform its consulting. The outputs (without naming specific attendees) are often summarized in insight reports that become reference material for others in the field.
- Academic and Peer-Reviewed Contributions: Many Putnam team members have strong academic credentials, and some continue to contribute to scientific literature. It’s not uncommon for Putnam consultants (especially those with PhDs/MDs) to co-author articles in peer-reviewed journals or present research at academic conferences. For example, a Putnam principal with a public health background might publish an article in a journal like Health Economics or The Lancet Public Health on a topic overlapping with industry, such as cost-effectiveness of new interventions or analysis of real-world treatment patterns. These contributions help maintain the firm’s scientific credibility. When clients see that Putnam staff have published in top journals or that they stay engaged in scientific discourse, it reinforces the message that Putnam’s advice is grounded in robust evidence and not just business buzzwords.
- Thought Leadership Partnerships: Under Inizio, Putnam can also collaborate with other divisions to create comprehensive thought leadership pieces. For instance, Putnam might team up with Research Partnership (an Inizio company) to produce a report on patient-centric launch strategies, combining market research data (from Research Partnership) with strategic recommendations (from Putnam). Such joint white papers or webinars can reach a broad audience. Additionally, Putnam occasionally contributes to media outlets – for example, writing an op-ed in PharmExec magazine about the evolving pharmaceutical commercial model, or being quoted in industry news articles (such as PharmaPhorum or FiercePharma) when expert commentary is needed on trends like drug pricing debates.
- Awards and Rankings: While not thought leadership per se, Putnam’s recognition in industry rankings enhances its influence. The firm’s consistent high rankings in Vault’s consulting lists (e.g., #1 boutique consulting firm multiple times, top 5 in innovation, top 10 overall, etc.) have been publicized via press releases and LinkedIn posts. Putnam being ranked highly for innovation, diversity, and overall consulting excellence feeds into its brand image as a cutting-edge and progressive firm in the life sciences domain. Clients and recruits see these accolades, which reinforces that Putnam isn’t just keeping up with the field – in some respects, it’s leading it.
All these activities contribute to an image of Putnam as a thought leader in life sciences consulting. The firm influences how companies think about issues like market access or medical affairs by sharing knowledge and shaping discussions. Importantly, this thought leadership is not just marketing; it reflects genuine expertise. Many life science executives follow Putnam’s published insights or attend sessions where Putnam speaks to stay informed – in that sense, Putnam helps set the agenda on critical industry topics (for example, how to incorporate patient voice into strategy, or how to use data to drive commercialization decisions).
Additionally, Putnam’s consultants themselves are encouraged to develop as thought leaders. The firm fosters a mindset where team members at all levels contribute ideas and research. Junior consultants might help in drafting an insight article or in preparing conference materials, which is both a learning experience and a way to get recognition. This culture means Putnam’s influence will likely continue to grow, as new voices from the firm add to the conversation on improving healthcare innovation and access.
Consulting Firm Profiles:
- Accenture
- Accordion Consulting
- Advisory Board
- AlixPartners
- Alvarez and Marsal
- Altman Solon Consulting
- Analysis Group
- Ankura Consulting Group
- Archstone Consulting (Acquired by The Hackett Group, Inc)
- Arthur D. Little
- Arthur J. Gallagher & Co.
- Arcadis
- Aon Consulting Services
- Arup Group
- Atos Group and Atos Consulting
- Bain & Company
- Baker Tilly International
- Bates White Economic Consulting
- BDO Consulting
- BearingPoint
- Berkeley Research Group
- BNP Paribas CIB Consulting & Transformation
- Booz Allen Hamilton
- Boston Consulting Group
- Bridgespan Group
- Capco Consulting
- Capgemini
- Capgemini Invent
- Carpedia International Consulting
- CGI Inc.
- Charles River Associates (CRA)
- Chemonics International Inc.
- ClearView Healthcare Partners
- Coalition Greenwich
- Cognizant Technology Solutions
- Compass Lexecon
- Computer Sciences Corporation (CSC) and Evolution into DXC Technology
- Cornerstone Research
- Corporate Executive Board (CEB)
- Crowe Global and Crowe LLP
- Dalberg Global Development Advisors
- Deloitte
- DGC Partners LLC
- dss+ (Formerly DuPont Sustainable Solutions)
- Environmental Resources Management (ERM)
- Everest Group (acquired by Wavestone)
- EVERSANA and EVERSANA CONSULTING
- EXL Service
- EY Consulting
- EY-Parthenon
- FTI Consulting
- FTI Delta (formerly Delta Partners)
- Forvis Mazars
- Galt & Company (acquired by AlixPartners)
- Gartner Inc. and Gartner Consulting
- GEP Worldwide
- ghSMART Consulting
- Grant Thornton Consulting – U.S. and Global
- Guidehouse
- Hay Group (acquired by Korn Ferry)
- HCL Axon Consulting
- HCLTech Consulting
- HDR, Inc.
- Health Advances Consulting
- Hewitt Associates (acquired by Aon)
- Hitachi Consulting (acquired by Hitachi Vantara)
- HP Enterprise Services Consulting (acquired by Hewlett Packard Enterprise)
- Horváth & Partners Consulting
- Huron Consulting Group
- IDEO
- IBM Consulting
- Infosys Ltd and Infosys Consulting
- Information Services Group (ISG) Consulting
- IQVIA Consulting Business
- INSIGHT2PROFIT Consulting
- Ipsos Consulting
- Jacobs Solutions Consulting
- John Wood Group PLC
- Kantar
- Kearney
- Korn Ferry
- KPMG
- Kroll (formerly Duff and Phelps)
- Kurt Salmon (acquired by Accenture)
- Larx Advisors Consulting
- Launch Consulting Group
- Leidos
- L.E.K. Consulting
- LTIMindtree
- Maine Pointe Consulting (acquired by SGS Group)
- Marakon Consulting
- Marsh & McLennan
- Mars & Co
- Mastercard Advisors and Mastercard Data & Services Division
- McKinsey & Company
- Mercer Consulting
- Metyis
- Miller Heiman Group
- Mitchell Madison Group
- Monitor Deloitte
- Mott MacDonald
- Navigant Consulting (acquired by Guidehouse)
- NERA Economic Consulting
- Newton Consulting Partners
- North Highland Consulting
- NTT DATA Consulting and NTT DATA Inc
- OC&C Strategy Consultants
- Oliver Wyman
- PA Consulting
- Palm Tree LLC
- Parsons Corporation
- Partners in Performance (acquired by Accenture)
- Point B Inc.
- Pointe Advisory
- Porsche Consulting
- ProcureAbility
- Propeller Consulting LLC
- Protiviti
- PRTM Consulting (acquired by PwC)
- Putnam
- PwC Consulting and Strategy&
- Ramboll
- RAND Corporation
- Riveron Consulting
- RGP Global Consulting Firm
- Roland Berger
- RSM International
- Schlumberger Business Consulting (acquired by Accenture)
- Science Applications International Corporation (SAIC)
- ScottMadden Consulting
- Simon-Kucher & Partners
- Slalom Consulting
- SSA & Company
- Stantec
- Strategy& (PwC)
- St. Onge Company
- Syneos Health Consulting
- SynFiny Advisors
- Targus Management Consulting AG
- Tata Consultancy Services
- Teneo Consulting
- Tetra Tech Consulting
- The Brattle Group
- The Cambridge Group
- The Chartis Group
- The Hackett Group
- Tompkins Solutions
- TriVista Consulting
- Visa Consulting & Analytics (VCA)
- Wavestone Consulting
- West Monroe Partners
- Willis Towers Watson Consulting
- Wilson Perumal & Company
- Wipro Consulting
- Worley
- WSP Global
- Xynteo
- ZS